Please use this identifier to cite or link to this item:
http://cmuir.cmu.ac.th/jspui/handle/6653943832/54686
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Georges Juvelekian | en_US |
dc.contributor.author | Waleed El-Sorougi | en_US |
dc.contributor.author | Chaicharn Pothirat | en_US |
dc.contributor.author | Faisal Yunus | en_US |
dc.contributor.author | Teresita De Guia | en_US |
dc.contributor.author | Han Pin Kuo | en_US |
dc.contributor.author | Shalma Basu Patnaik | en_US |
dc.contributor.author | Virginia Pilipovic | en_US |
dc.date.accessioned | 2018-09-04T10:20:47Z | - |
dc.date.available | 2018-09-04T10:20:47Z | - |
dc.date.issued | 2015-10-05 | en_US |
dc.identifier.issn | 11782005 | en_US |
dc.identifier.issn | 11769106 | en_US |
dc.identifier.other | 2-s2.0-84943607194 | en_US |
dc.identifier.other | 10.2147/COPD.S83071 | en_US |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84943607194&origin=inward | en_US |
dc.identifier.uri | http://cmuir.cmu.ac.th/jspui/handle/6653943832/54686 | - |
dc.description.abstract | © 2015 Juvelekian et al. Aim: INFLOW (INdacaterol eFfectiveness and utiLizatiOn in COPD: real World evaluation) was a prospective, noninterventional study assessing the effectiveness and safety of long-acting bronchodilators in patients with chronic obstructive pulmonary disease (COPD) from the Middle East, Asia, and South Africa. Methods: Patients newly prescribed or switched to indacaterol or other long-acting β2-agonist (LABA), or tiotropium (monotherapy or in combination) were evaluated over 6 months. The primary endpoint was the clinical COPD questionnaire overall score at the end of the study. Results: Data were analyzed from 1,710 patients (mean postbronchodilator forced expiratory volume in 1 second, 59% predicted) who received indacaterol (n=1,179), other LABA (n=68), tiotropium (n=271), indacaterol plus tiotropium (n=167), or other LABA plus tiotropium (n=25). Across treatments, clinical COPD questionnaire overall score improved from baseline by 0.81–1.26 points (all P,0.0001), 63%–84% of patients were satisfied/very satisfied, and physicians rated effectiveness as good/very good in 63%–80% of cases. The indacaterol inhaler was rated easy/very easy to use by the majority of patients, and physicians considered its use clearly understood by most patients. All treatments had acceptable tolerability. Conclusion: In real life clinical practice across a diverse region, indacaterol and other long-acting bronchodilators improved health status and were well regarded by patients and physicians. | en_US |
dc.subject | Medicine | en_US |
dc.title | Areal-world evaluation of indacaterol and other bronchodilators in COPD: The INFLOW study | en_US |
dc.type | Journal | en_US |
article.title.sourcetitle | International Journal of COPD | en_US |
article.volume | 10 | en_US |
article.stream.affiliations | Saint George Hospital University Medical Center | en_US |
article.stream.affiliations | Helwan University | en_US |
article.stream.affiliations | Chiang Mai University | en_US |
article.stream.affiliations | Universitas Indonesia | en_US |
article.stream.affiliations | Philippine Heart Center | en_US |
article.stream.affiliations | Chang Gung Memorial Hospital | en_US |
article.stream.affiliations | Novartis Healthcare Pvt. Ltd. | en_US |
article.stream.affiliations | Novartis International AG | en_US |
Appears in Collections: | CMUL: Journal Articles |
Files in This Item:
There are no files associated with this item.
Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.